title: Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats.
abstract: Metabolic syndrome, encompassing type 2 diabetes mellitus and cardiovascular disease, is a growing health concern of industrialized countries. Ferulic acid (FA) is a phenolic acid found in foods normally consumed by humans that has demonstrated antioxidant activity, cholesterol-lowering capabilities, and anti-tumorigenic properties. Select probiotic bacteria, including Lactobacillus fermentum NCIMB 5221, produce FA due to intrinsic ferulic acid esterase activity. The aim of the present research was to investigate a FA-producing probiotic, L. fermentum NCIMB 5221, as a biotherapeutic for metabolic syndrome. The probiotic formulation was administered daily for 8 weeks to Zucker diabetic fatty (ZDF) rats, a model of hyperlipidemia and hyperglycemia. Results show that the probiotic formulation reduced fasting insulin levels and insulin resistance, significantly reduced serum triglycerides (p = 0.016), lowered serum low-density lipoprotein cholesterol levels (p = 0.008), and significantly reduced the atherogenic (p = 0.016) and atherosclerosis (p = 0.012) index as compared to the control animals. In addition, the probiotic formulation significantly increased high-density lipoprotein cholesterol levels (p = 0.041) as compared to the control animals. This research indicates that administration of the FA-producing L. fermentum NCIMB 5221 has the potential to reduce insulin resistance, hyperinsulinemia, hypercholesterolemia, and other markers involved in the pathogenesis of metabolic syndrome. Further studies are required to investigate the human clinical potential of the probiotic formulation in affecting the markers and pathogenesis of metabolic syndrome.
authors.forename: Catherine
authors.initials: C
authors.lastname: Tomaro-Duchesneau
authors.forename: Shyamali
authors.initials: S
authors.lastname: Saha
authors.forename: Meenakshi
authors.initials: M
authors.lastname: Malhotra
authors.forename: Mitchell L
authors.initials: ML
authors.lastname: Jones
authors.forename: Alain
authors.initials: A
authors.lastname: Labbé
authors.forename: Laetitia
authors.initials: L
authors.lastname: Rodes
authors.forename: Imen
authors.initials: I
authors.lastname: Kahouli
authors.forename: Satya
authors.initials: S
authors.lastname: Prakash
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003373:Coumaric Acids / Q000378:metabolism*; D004195:Disease Models, Animal; D007328:Insulin / Q000097:blood; D052197:Limosilactobacillus fermentum / Q000254:growth & development* / Q000378:metabolism*; D024821:Metabolic Syndrome / Q000473:pathology* / Q000628:therapy*; D019936:Probiotics / Q000008:administration & dosage* / Q000378:metabolism*; D051381:Rats; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003373:Coumaric Acids; D007328:Insulin; D014280:Triglycerides; C004999:ferulic acid